This study use a single-center, randomized, open, three-cycle, self-control trial design utilizing the drug Hetrombopag olamine, a non-peptide thrombopoietin (TPO) receptor agonist that attempts to increase platelet production.

China

https://clinicaltrials.gov/ct2/show/NCT03603132?cond=ITP&cntry=CN&rank=46

Recruiting